SCM
ALNY icon

Sterneck Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Sterneck Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-14,235
Closed -$911K – 144
2013
Q3 		$911K Sell
14,235
-5,850
-29% -$292K 0.58% 55
2013
Q2 		$623K Buy
+20,085
New +$534K 0.39% 75

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CWAM
Columbia Wanger Asset Management Chicago, Illinois $6.69B AUM 31.14% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Sterneck Capital Management's ALNY Position: Q4 2013 in Review

Sterneck Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2013, closing a stake of 14,235 shares — an estimated $911K sold.

Sterneck Capital Management first reported a position in ALNY in Q2 2013 and held it in 2 quarters. The position peaked at $911K in Q3 2013. 169 funds tracked by Wall St. Rank hold ALNY as of Q4 2013.

  • Sterneck Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q4 2013 after selling out during the quarter.
  • Sterneck Capital Management sold 14,235 Alnylam Pharmaceuticals shares in Q4 2013, an estimated $911K.
  • Sterneck Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2013 and held it in 2 quarters.
  • Sterneck Capital Management's Alnylam Pharmaceuticals position peaked at $911K in Q3 2013.
  • 169 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2013.

Based on Sterneck Capital Management's 13F filing for Q4 2013, filed 7 Feb 2014.